Updated Jul 16, 2026
Welgus Howard G. has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.95M.
Howard G. Welgus is a corporate director at Arcutis Biotherapeutics, Inc., a company focused on developing treatments for immune-mediated dermatological diseases. He has been involved in multiple SEC filings related to his role, indicating an active participation in the company's governance.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 635 | $25.67 | $16K |
| 2026-06-18 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 4.1K | $24.41 | $100K |
| 2026-06-18 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 2.3K | $8.63 | $19K |
| 2026-06-18 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 1.0K | $7.51 | $8K |
| 2026-06-18 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 822 | $6.52 | $5K |
| 2026-06-10 | ARQT | Arcutis Biotherapeutics, Inc. | A — Grant or award | 5.8K | $0.00 | |
| 2026-05-06 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 7.1K | $22.99 | $164K |
| 2026-04-03 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale [10b5-1] | 10.0K | $23.88 | $239K |
| 2026-03-04 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale [10b5-1] | 10.0K | $25.65 | $257K |
| 2026-02-05 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale [10b5-1] | 10.0K | $25.05 | $250K |
| 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 462 | $18.92 | $9K |
| 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 9.5K | $18.92 | $180K |
| 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 9.5K | $1.68 | $16K |
| 2025-09-02 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 10.0K | $15.64 | $156K |
| 2025-09-02 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 10.0K | $0.00 | |
| 2025-08-01 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 3.9K | $14.30 | $56K |
| 2025-08-01 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 3.9K | $0.00 | |
| 2025-08-01 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 6.1K | $14.30 | $87K |
| 2025-08-01 | ARQT | Arcutis Biotherapeutics, Inc. | M — Option exercise | 6.1K | $0.00 | |
| 2025-07-01 | ARQT | Arcutis Biotherapeutics, Inc. | S — Open-market sale | 9.2K | $13.84 | $127K |
Howard G. Welgus is a corporate director at Arcutis Biotherapeutics, Inc., a company focused on developing treatments for immune-mediated dermatological diseases. He has been involved in multiple SEC filings related to his role, indicating an active participation in the company's governance.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 15 open-market sales ($1.95M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Welgus Howard G. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.